Sagamore Investments

About The Fund

Founded in 2002, Sagamore Investments is a private equity and fund of funds firm with a strategic focus on sectors including BioTech, Life Science, and fintech. They have offices in Beijing, China, and Hong Kong and prioritize investments in high-growth Chinese markets. Their investment thesis centers on supporting today's consumption and tomorrow's innovation in China, with particular emphasis on industries transformed by global leaders in artificial intelligence, the surge in Chinese consumer behavior towards upgraded lifestyle choices, fintech innovations spurred by a substantial Internet user base and an underdeveloped banking industry, as well as the dramatic expansion of the Chinese middle class. Sagamore Investments commits to improving healthcare and medical services while also developing new drugs. They collaborate with venture capital and growth capital funds to access category-leading companies at each stage of the capital and innovation cycle. They provide seed and early-stage funding through venture capital and capitalize on broad economic expansion through growth equity, plus partner with later-stage investors to support market leaders preparing for M&A and IPO transactions. Sagamore makes direct investments in founders who build businesses aligned with China's consumption upgrade in areas such as fintech, healthcare, artificial intelligence, and education. They have taken part in significant transactions such as the landmark take-private of WuXi AppTec in 2015. Their portfolio includes Momenta, a leader in autonomous driving technology; WuXi AppTec, providing R&D and manufacturing services for life sciences; and Neat, which delivers digital banking services. Sagamore's investment size ranges from a minimum of $3,000,000 to a maximum of $22,000,000, demonstrating flexibility and commitment to scaling innovative companies in the region.